NCT05846659: A reported trial by ImmuneSensor Therapeutics Inc.
This trial has reported on time, in line with the regulations.
Full data
| Full entry on ClinicalTrials.gov | NCT05846659 |
|---|---|
| Title | Phase 2 Randomized Clinical Trial Comparing the Safety and Efficacy of PULSAR-Integrated Radiotherapy + Pembrolizumab or Nivolumab Administered with or Without STING-Agonist IMSA101 in Patients with Oligoprogressive Solid Tumor Malignancies |
| Results Status | Reported |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | July 7, 2023 |
| Completion date | Nov. 20, 2024 |
| Required reporting date | Nov. 20, 2025, midnight |
| Actual reporting date | Nov. 11, 2025 |
| Date last checked at ClinicalTrials.gov | Jan. 7, 2026 |
| Days late | None |